CStone Pharmaceuticals has announced the publication of long-term survival data from its Phase III GEMSTONE-302 trial on Sugemalimab in The Lancet Oncology. The company, focused on the development of anti-cancer therapies, has made significant progress with this trial. The publication of these results marks an important milestone for CStone, as it continues to address unmet medical needs in cancer treatment. CStone has successfully launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. The company emphasizes cautious engagement with its securities, advising shareholders and potential investors to exercise diligence when dealing with company shares.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。